Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. (NYSE: DVA) is a comprehensive kidney care provider whose news flow reflects its clinical, operational and financial activities in the kidney dialysis centers industry. Company press releases and updates highlight its focus on transforming care delivery for patients with kidney disease, its large global network of outpatient dialysis centers and its role in integrated kidney care and value-based care models.
News about DaVita often covers quarterly financial and operating results, where the company reports consolidated revenues, operating income, cash flow and key U.S. dialysis metrics such as treatment volumes, revenue per treatment and patient care costs per treatment. These releases may also discuss share repurchases, debt transactions, credit facility amendments and guidance ranges for adjusted operating income, adjusted diluted net income per share and free cash flow.
Investors and observers can also find updates on clinical research and innovation. DaVita publishes information about studies presented at events like the American Society of Nephrology’s Kidney Week, including research on GLP-1 receptor agonist use in end-stage kidney disease, home dialysis outcomes, transplant access and end-of-life care. Additional news may describe initiatives such as the MODEL and MEMOIRS evaluations of medium cut-off dialyzers and efforts to better understand middle-molecule clearance.
Other DaVita news items include leadership appointments, participation in investor conferences and statements on government programs such as the Kidney Care Choices (KCC) Model. These communications provide insight into the company’s strategy, governance, integrated kidney care footprint and engagement with value-based care initiatives. For ongoing context on DVA, readers can use this news feed to follow developments in DaVita’s kidney care operations, research programs and capital allocation decisions over time.
In November 2021, DaVita and the American Diabetes Association (ADA) collaborate for American Diabetes Month, focusing on the link between diabetes and kidney disease. The initiative aims to educate and provide resources, having reached 35 million people to date. About 1.5 million Americans are diagnosed with diabetes annually, and 37 million live with kidney disease. The campaign promotes preventive measures and includes live discussions and access to kidney-friendly resources. DaVita serves 241,600 patients across over 3,100 outpatient dialysis centers globally.
DaVita Inc. (NYSE: DVA) reported strong financial results for Q3 2021, achieving diluted earnings per share of $2.36, up 84.4% year-over-year. Consolidated revenues reached $2.938 billion, with operating income at $475 million. Operating cash flow was $567 million and free cash flow was $358 million. The company repurchased 2.731 million shares at an average cost of $123.14. Despite challenges from COVID-19 and a tough labor market, DaVita continues to deliver quality care and execute its strategic plan.
DaVita Inc. (NYSE: DVA) will hold a virtual Capital Markets Day on November 16, 2021, from 10:00 a.m. to 12:00 p.m. Eastern Time. Investors can join the live webcast through a provided link on their investor website. The event will discuss the company’s strategies and performance, emphasizing its commitment to improving quality of life for patients while being one of the largest kidney care providers in the U.S. As of June 30, 2021, DaVita served over 204,300 patients across 2,828 outpatient dialysis centers in the U.S. and operates internationally.
DaVita Inc. (NYSE: DVA) will hold its quarterly conference call on October 28, 2021, at 5:00 p.m. Eastern Time to discuss its third quarter results. The results will be available after market close that day. Interested parties can listen via webcast on the DaVita investor relations website, or by dialing in using the provided numbers. DaVita is a leading kidney care provider that serves over 204,300 patients at 2,828 outpatient dialysis centers in the U.S. and operates an additional 331 centers globally.
Summary not available.
DaVita Kidney Care announces the appointment of Tina Livaudais as the new chief nursing officer (CNO) during Nephrology Nurses Week. Livaudais brings over 26 years of experience with DaVita, serving in various clinical and leadership roles. As CNO, she aims to enhance clinical excellence and professional growth for nursing staff. The company continues to focus on improving patient care, aiming to be the preferred provider and employer in the kidney care sector. DaVita operates 2,828 outpatient dialysis centers in the U.S., caring for over 204,300 patients.
DaVita Inc. appointed Dr. Gregory Moore as an independent director effective Sept. 9, 2021. With nearly 20 years of healthcare experience, Dr. Moore currently leads Microsoft's Health & Life Sciences division, focusing on digital transformation in healthcare. CEO Javier Rodriguez emphasized that Dr. Moore's expertise will enhance DaVita's efforts to innovate kidney care solutions. Dr. Moore will participate in the Nominating and Governance Committee and the Compliance and Quality Committee. This addition strengthens the Board's diversity, with 33% racial/ethnic and 44% gender representation.
DaVita reported strong financial results for Q2 2021, with diluted earnings per share of $2.64, a 63% increase year-over-year. Consolidated revenues reached $2.917 billion, while operating income was $490 million. The company experienced a solid operating cash flow of $680 million and free cash flow of $503 million. DaVita's ongoing investment in integrated kidney care is expected to drive growth, increasing patients under value-based care arrangements to approximately 10% of its U.S. dialysis patient base. The company also repurchased over 2 million shares this quarter.
DaVita Inc. (NYSE: DVA) announced a quarterly conference call to discuss its second quarter results on August 3, 2021, at 5:00 p.m. Eastern Time. The results will be released after market close on the same day. Investors can join the call via phone or webcast. DaVita is focused on improving kidney care services, treating patients with chronic kidney failure, and has become the leading provider of home dialysis in the U.S., serving over 202,600 patients across 2,827 outpatient dialysis centers.
DaVita and the National Kidney Foundation (NKF) have partnered to launch a yearlong pilot program aimed at enhancing health equity in kidney transplantation. This initiative will be implemented in Colorado, New York, Minnesota, and New Mexico, focusing on empowering kidney patients to find living donors. The program will offer extensive support, including one-on-one guidance from Patient Navigators and access to a new web platform for education. With over 500,000 individuals in the U.S. living with kidney failure and nearly 100,000 awaiting a transplant, this collaboration seeks to improve donor accessibility and patient outcomes.